Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Checkpoint-blockade immunotherapy has transformed cancer therapeutics but still benefits only a subset of patients. The development of more-robust biomarkers of response could change that.
New initiatives aimed at reducing the burden of diabetes are laudable, but they will have to account for the disease’s complexity and heterogeneity to be truly effective and equitable at a global scale.
In this issue, Nature Medicine presents the Burden of Proof studies led by the Institute for Health Metrics and Evaluation, which quantitatively evaluate the strength of evidence of risk–outcome relationships to better inform effective clinical and policy recommendations.
The US Supreme Court’s majority decision to overturn the constitutional protection of the right to seek an abortion threatens the health of all Americans.
We are raising the standards on reporting on sex and gender in research. Starting this June, authors will be prompted to provide details on how sex and gender were considered in study design.
With the increase in genomic data available and the advent of new technology for mining it, balancing the needs for data sharing and data protection becomes more challenging. Different disciplines must come together to find new solutions.
New treatments and technologies offer exciting prospects for cancer research and care, but their global impact rests on widespread implementation and accessibility.
The use of transgenic pigs as a source of organs and tissues for patients in need could revolutionize medicine — but to achieve that goal, data from clinical trials and forthright assessment of the ethics of animal-to-human transplants will be critical.
It is time to close a loophole that allows certain types of diagnostic lab tests to be exempt from regulatory oversight, putting people at risk of making consequential medical decisions on the basis of unreliable results.
The Glasgow Climate Pact reaffirms countries’ commitments to limiting global heating to 1.5 °C, but without prioritizing health, equity and multisectoral engagement within climate action, the health of the planet and the future of humanity remain at grave risk.
